- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProKidney Corp (PROK)
Track the ProKidney share price today and view real-time PROK share price data, including charts, technicals, and key financials. View the PROK premarket stock price ahead of the market session or assess the after hours quote. Explore PROK stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the ProKidney Stock Price Today?
The ProKidney stock price today is 1.140.
What Is the Stock Symbol for ProKidney?
The stock symbol for ProKidney is ""PROK.""
What Stock Exchange Does ProKidney Trade On?
ProKidney is listed and trades on the NASDAQ stock exchange.
Is ProKidney a Good Stock to Buy?
Determining whether ProKidney or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PROK quote. (ISIN: US74291D1046)
What Is the ProKidney Stock Price Today?
The ProKidney stock price today is 1.140.
What Is the Stock Symbol for ProKidney?
The stock symbol for ProKidney is ""PROK.""
What Stock Exchange Does ProKidney Trade On?
ProKidney is listed and trades on the NASDAQ stock exchange.
Is ProKidney a Good Stock to Buy?
Determining whether ProKidney or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PROK quote. (ISIN: US74291D1046)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.040
1.160
52 wk Range
0.870
2.950
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0401.160
52 wk Range
0.8702.950
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PROK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.500
Upside
+470.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 4 ProKidney Corp For: 15 June- Investing.com
Form 8K ProKidney Corp For: 29 October- Investing.com
ProKidney receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 8K ProKidney Corp For: 29 October
- Investing.com
- ProKidney receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
ProKidney earnings missed, revenue topped estimates- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.500
(+470.18% Upside)
Earnings
Latest Release
10/08/2026
EPS / Forecast
-0.15 / -0.14
Revenue / Forecast
150K / 129.75K
Compare PROK to Peers and Sector
Metrics to compare | PROK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.1x | −1.5x | −0.2x | |
PEG Ratio | −2.32 | 0.01 | 0.00 | |
Price/Book | −0.4x | 2.7x | 2.6x | |
Price / LTM Sales | 421.3x | 5.3x | 2.8x | |
Upside (Analyst Target) | - | 154.9% | 65.6% | |
Fair Value Upside | Unlock | 22.4% | 10.0% | Unlock |
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the ProKidney (PROK) Stock Price Today?
The ProKidney stock price today is 1.140 USD.
What Stock Exchange Does ProKidney Trade On?
ProKidney is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ProKidney?
The stock symbol for ProKidney is "PROK."
What Is the ProKidney Market Cap?
As of today, ProKidney market cap is 321.970M USD.
What Is ProKidney's Earnings Per Share (TTM)?
The ProKidney EPS (TTM) is -0.56.
When Is the Next ProKidney Earnings Date?
ProKidney will release its next earnings report on 16/11/2026.
From a Technical Analysis Perspective, Is PROK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has ProKidney Stock Split?
ProKidney has split 0 times.
How Many Employees Does ProKidney Have?
ProKidney has 231 employees.
What is the current trading status of ProKidney (PROK)?
As of 07/11/2026, ProKidney (PROK) is trading at a price of 1.140 USD, with a previous close of 1.140 USD. The stock has fluctuated within a day range of 1.040 USD to 1.160 USD, while its 52-week range spans from 0.870 USD to 2.950 USD.
What Is ProKidney (PROK) Price Target According to Analysts?
The average 12-month price target for ProKidney is 6.500 USD, with a high estimate of 12 USD and a low estimate of 1 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +470.18% Upside potential.
What Is the PROK Premarket Price?
PROK's last pre-market stock price is 1.060 USD. The pre-market share volume is 530.000, and the stock has decreased by -0.005, or -0.470%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.